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Introduction: Cyclophilin A (CypA) is implicated in rheumatoid arthritis (RA) pathogenesis. We studied whether a
novel anti-CypA single domain antibody (sdAb) treatment would modulate the severity of the disease in two
different animal models of RA.
Methods: A novel sdAb, named sdAbA1, was screened from an immunized camel sdAb library and found to have
a high binding affinity (KD = 6.9 × 10
-9 M) for CypA. The SCID-HuRAg model and the collagen-induced arthritis (CIA)
in mice were used to evaluate the effects of sdAbA1 treatment on inflammation and joint destruction. For in vitro
analysis, monocytes/macrophages were purified from synovial fluid and peripheral blood of patients with RA and
were tested for the effect of anti-CypA sdAb on metalloproteinase (MMP) production. Human monocyte cell line
THP-1 cells were selected and western blot analyses were performed to examine the potential signaling pathways.
Results: In the CIA model of RA, the sdAbA1 treatment resulted in a significant decrease in clinical symptoms
as well as of joint damage (P <0.05). In the SCID-HuRAg model, treatment with anti-CypA antibody sdAbA1
significantly reduced cartilage erosion, inflammatory cell numbers and MMP-9 production in the implanted tissues
(P <0.05). It also significantly reduced the levels of human inflammatory cytokines IL-6 and IL-8 in mouse serum
(P <0.05). No toxic effects were observed in the two animal models. In vitro results showed that sdAbA1 could
counteract CypA-dependent MMP-9 secretion and IL-8 production by interfering with the ERK-NF-κB pathway.
Conclusions: Blockade of CypA significantly inhibited synovitis and cartilage/bone erosion in the two tested animal
models of RA. Our findings provide evidence that sdAbA1 may be a potential therapeutic agent for RA.* Correspondence: wanglifw@fmmu.edu.cn; liyufmmu@yahoo.com; znchen@
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Rheumatoid arthritis (RA) is a chronic and debilitating
disease of the joints characterized by synovial inflamma-
tion and progressive destruction of articular cartilage and
bone [1]. The number of inflammatory cells and the level
of inflammatory cytokines in the joints correlate with the
extent of synovitis, and matrix metalloproteinases (MMPs)
at the cartilage–pannus junction of RA patients are the
main proteases involved in the invasion and degradation
of cartilage [2]. In RA, the number of monocytes/macro-
phages, which secrete multiple cytokines [3] and MMPs,
is significantly increased in both the lining and sublining
areas of the RA synovium, where they play a critical role
in inflammation and joint destruction.
Cyclophilins are a novel family of proteins exerting po-
tent chemotactic capacity that have been well researched
recently. Cyclophilins are widely expressed intracellular
proteins, well known as receptors for the immunosuppres-
sive drug cyclosporine A (CsA). Cyclophilin A (CypA) is
the most abundant cyclophilin and can be actively released
into extracellular tissue spaces in response to inflamma-
tory stimuli [4]. Extracellular CypA is not only a strong
in vitro chemoattractant for neutrophils, T cells and
monocytes, but can also induce a rapid influx of leuko-
cytes in vivo [5]. High levels of CypA have been detected
in the serum and synovial fluid of RA patients and the
amount of CypA was closely related to disease severity [6].
In RA synovium, CypA has been detected in most of mac-
rophages in the lining layer and sublining area, and CypA
staining overlaps with MMP-9 staining [7]. Our previous
study claims that CypA upregulates MMP-9 expression
and adhesion of monocytes/macrophages [8], and may ag-
gravate cartilage erosion when injected in vivo [9]. Taken
together, these results show that CypA plays an important
role in the pathogenesis of RA and that reagents targeting
CypA could be beneficial in the treatment of this disease.
Monoclonal antibodies have played vital roles in
antibody-based therapies against various diseases includ-
ing RA [10]. Nevertheless, difficulties such as the costs
of production and protein stability can be encountered.
Recent major progress involved the use of single-domain
antibodies (sdAbs) derived from camelids. In addition to
conventional antibodies, camelids produce antibodies
composed of heavy chains only, with a single variable
domain (referred to as VHH) capable of recognizing spe-
cific antigens. These variable domains, named sdAbs, are
the smallest naturally occurring, intact antigen-binding
units and are highly valuable for their unique features.
SdAbs are easily produced by bacterial fermentation.
This approach implies an estimated 10-fold reduction in
production costs as compared with conventional thera-
peutic antibodies, which are all produced in mammalian
systems [11]. The long CDR3 in sdAbs recognizes struc-
tures such as pockets and clefts on the surface ofantigens that are inaccessible for conventional anti-
bodies. Other attractive features of sdAbs include high
solubility, thermal stability, and low immunogenicity to
humans [12]. A number of sdAbs have also been devel-
oped to treat a spectrum of human diseases, and some
are currently in the late stages of clinical trials. For ex-
ample, two antibodies, ozoralizumab (an anti-tumor ne-
crosis factor (TNF)-alpha sdAb) and ALX-0061 (an
interleukin (IL)-6R sdAb), are also in phase II trials [13].
The efficacy of CsA on animal models for RA is so far
not satisfactory, even paradoxical [14]. A few other CypA
inhibitors, such as the CsA derivative SDZ NIM811,
capable of inhibiting neutrophil influx in vivo have been re-
ported [5]. However, previous studies focused on the ability
of CypA to regulate chemotaxis, and did not investigate
other critical functions of CypA, such as the stimulation of
MMP secretion that leads to cartilage destruction. Until
now, there have been no reports of CypA-specific anti-
bodies used for the treatment of RA. In this study, we char-
acterized a new sdAb that was shown to inhibit important
biological functions of CypA both in vitro and in vivo.
Materials
Animals and patient samples
The DBA/1 mice and the NOD/SCID mice were purchased
from Shanghai Laboratory Animal Co. Ltd (Shanghai,
China). Peripheral blood and synovial fluid were obtained
from patients with active RA and the synovium tissues
were obtained from RA patients undergoing joint replace-
ment surgery or synovectomy. All of the RA patients met
the 1987 revised diagnostic criteria of the American College
of Rheumatology [15]. The normal human cartilage speci-
mens were obtained from nonarthritis patients with fem-
oral head fractures. Ethics approval was granted from the
Ethics Committee of Fourth Military Medical University.
All patients gave their informed consent to participate in
this study. Likewise, all experiments involving animals were
reviewed and approved by the Laboratory Animal Center
of Fourth Military Medical University.
Cells isolation and culture
The human monocytes were purified from peripheral
blood of the RA patients using the Monocyte Negative
Isolation kit (Invitrogen, Grand Island, NY, USA), and 1 ×
106 cells/ml were cultured in 2 ml RPMI 1640 with 10%
fetal bovine serum (Gibco, Grand Island, NY, USA) with
15 ng/ml recombinant human macrophage colony-
stimulating factor (R&D System, Emeryville, CA, USA) in
six-well plates at 37°C. Macrophages were used after 7 days
of culture. For synovial fluid of RA patients, monocytes/
macrophages were isolated by Dynabeads® CD14 (Invitro-
gen) according to the manufacturer’s instructions.
The human monocytic THP-1 cells (American Type
Culture Collection, Manassas, VA, USA) were cultured in
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serum at 37°C in 5% carbon dioxide. For the induction
of cell differentiation, cells (5 × 105 to 106/ml) were
stimulated with 100 nM phorbol 12-myristate 13-acetate
(Sigma-Aldrich, St. Louis, MO, USA) for 48 hours.
Library construction and single-domain antibody selection
Two adult male alpacas were immunized with endotoxin-
free recombinant human CypA [9] as described previously
[16]. Library construction and panning were performed as
described previously [17]. Following three rounds of pan-
ning, individual clones producing target-binding sdAbs
were identified by monoclonal phage enzyme-linked im-
munosorbent assay (ELISA). A horseradish peroxidase-
labeled anti-M13 monoclonal antibody (GE Healthcare,
Pittsburgh, PA, USA) diluted at 1:10,000 in phosphate-
buffered saline (PBS) was used as a secondary antibody.
The peroxidase enzyme activity was determined by adding
TMB as a substrate, and the signal was read by optical
density at 450 nm with a multiwell microplate reader
(Bio Tek Instruments, Norcross, GA, USA).
Four positive clones were recloned into the modified
expression vector pCANTAB5 His and were transformed
into HB2151 cells. An overnight culture from a single
colony was added to 2 × YT broth supplemented with 0.2%
glucose and 100 μg/ml ampicillin. This culture was grown
until the optical density at 600 nm reached 0.6 to 0.9. The
expression of sdAb was induced with 1 mM isopropyl
β-D-1-thiogalactopyranoside overnight at 30°C. Cells were
then pelleted, resuspended and ultrasonicated. The sdAb
protein fragments were purified by a combination of immo-
bilized metal-ion affinity chromatography using His Trap
HP metal affinity resin column (GE Healthcare) and size-
exclusion chromatography with HiLoad 16/60 Superdex 75
prep grade column (GE Lifesciences, Pittsburgh, PA, USA).
Protein was quantified with BCA Protein assay kit (Pierce,
Rockford, IA, USA), with BSA used as a standard.
Surface plasmon resonance measurements
The binding kinetics and affinity of sdAbA1 for purified
CypA protein were obtained using the ProteON XPR36
protein interaction array system (Bio-Rad Laboratories,
Hercules, CA, USA). A GLC chip was activated, on which
recombinant CypA protein (10 μg/ml, diluted in 10 mM
sodium acetate buffer, pH 4.5) was immobilized at 25°C in
the vertical orientation. Following that, the remaining carb-
oxyl groups were blocked with 1 M ethanolamine–HCl
(pH 8.5). Finally, sdAbA1 (diluted in 10 mM phosphate
buffer with 150 mM NaCl, pH 7.4) was injected in the hori-
zontal orientation at five concentrations in twofold serial
dilution down from 24 nM to 1.5 nM at a flow rate of
50 μl/minute. Antibody binding was evaluated by simultan-
eously flowing six sdAb concentrations that ranging from 0
to 24 nM over the CypA-coated chip for 180 seconds, andthen monitoring dissociation for 720 seconds. The data
were analyzed with ProteON Manager™ 3.1 software
(Bio-Rad, Hercules, CA, USA), and binding constants were
determined using a 1:1 Langmuir binding model.
Peptidyl-prolyl cis–trans isomerase activity assay
The peptidyl-prolyl cis–trans isomerase (PPIase) activity was
determined in a coupled assay with chymotrypsin using the
tetrapeptide substrate Suc-Ala-Phe-Pro-Phe-p-nitroanilide
(Sigma, St. Louis, MO, USA) [18]. All reagents were pre-
equilibrated until the temperature reached 0°C. In a 1 ml
cuvette, purified CypA was mixed with 10 μl chymotrypsin
(20 μg/μl), and the volume was adjusted to 975 μl with assay
buffer (50 mM HEPES, 100 mM NaCl, pH 8.0). The
reaction was initiated by the addition of 25 μl tetrapeptide
substrate at a final concentration of 37.5 μM. Changes in
absorbance due to released p-nitroaniline were measured
every 10 seconds for a maximum of 250 seconds in a
spectrophotometer at 390 nm. Cleavage of the tetrapeptide
substrate in the absence of CypA was used as a blank con-
trol, and the addition of CypA was used as a positive control
for PPIase activity. CypA (PPIase inhibitor) was added at a
concentration of 5.0 μM. The effect of sdAbA1 on the
PPIase activity of CypA was performed with the pre-
incubation of CypA with sdAbA1 for 2 hours before
addition to the reaction system.
Induction, treatment, and assessment of collagen-induced
arthritis
The collagen-induced arthritis (CIA) model was con-
structed as described previously [19]. Male DBA/1 mice
were immunized intradermally at the base of the tail with
200 μg chicken type II collagen (Chondrex, Redmond, WA,
USA) emulsified in Freund’s complete adjuvant (BD
Biosciences, San Jose, CA, USA) at the age of 8 to 12 weeks.
On day 21 after primary immunization, mice were given a
booster injection intradermally using the same concentra-
tion of type II collagen but with Freund’s incomplete adju-
vant. Given that disease onset in this model varies widely
for each mouse, and that not all mice develop arthritis, we
in total used 100 mice to construct the CIA model. When
immunized mice started to show clinical symptoms, 30
arthritic mice (an animal exhibited a clinical score in the
range of 1 to 3 on day 27) were chosen to receive different
treatments and were randomly assigned in cages. Ten mice
were injected intraperitoneally with anti-CypA antibody
sdAbA1 at a dose of 5 mg/kg once a day between days 27
and 37 after primary immunization. As a control, the other
20 mice were given intraperitoneal injections with PBS or
isotype control (sdAbE2) at the same time points at which
sdAbA1 was given. Clinical severity was scored on a scale
of 0 to 4 as described previously [20]. The individual mouse
arthritic score was obtained by summing the scores
recorded for each limb. All clinical evaluations were
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treatment group to which the mouse belonged.
Assessment of radiographic joint damage in collagen-
induced arthritis
X-ray radiographs were taken (In Vivo Imaging System FX
PRO, Carestream, Riverside, CA, USA) of the hind paws of
mice that had been given a general anesthetic. The degree
of bone erosion in the ankle joint was scored as described
previously [21] (0 = no swelling or bone damage, 1 =mild
bone damage, 2 =moderate bone erosion, and 3 = severe
bone erosion). The severity of arthritis in each mouse was
determined independently and blindly by two observers.
Construction of the SCID-HuRAg model
The synovium tissues were obtained from six patients
with RA judged by American College of Rheumatology
criteria. None of the patients included in the study
had received treatment with corticosteroids or disease-
modifying anti-rheumatic drugs. The SCID-HuRAg
model was constructed as described previously [22]. In
brief, 6-week-old to 8-week-old male NOD/SCID mice
were used in this study. A 1 cm incision was made in
the left flank. Normal human cartilage and rheumatoid
synovial tissue were placed in the chamber in the muscle
using fine forceps. The entire procedure was performed
under sterile conditions.
Single-domain antibody A1 treatment
Four weeks after implantation, 24 mice were randomly
divided into four different treatment groups and were
randomly assigned to cages. SdAbA1 (5 mg/kg, n = 6),
infliximab (10 mg/kg, n = 6), sdAbE2 (5 mg/kg, n = 6) or
PBS (n = 6) was administered three times a week within
the implanted tissue using a micro-syringe. The injec-
tions were repeated over 4 weeks. The mice were anaes-
thetized and euthanized 7 days after the final injection
for the removal of the implanted tissue.
Histologic evaluation of SCID-HuRAg mice
The implanted tissues were removed from the SCID-
HuRAg mice, paraffin embedded, and stained with
hematoxylin and eosin for morphological evaluation.
The number of inflammatory cells per unit was counted
using Image-Pro Plus 6.0 (Media Cybernetics, Silver
Spring, MD, USA). With this system, cells with similar
characteristics (such as shape and size) can then be
counted. Three measurements were made for each unit
area, and the mean value was then calculated. The inva-
sion of synovial tissue into the cartilage was quantified
according to a semiquantitative score ranging from 0 to
4, based on the number of invading cell layers and the
number of affected cartilage sites. Erosion was scored on
a scale of 0 to 4 as described previously [23]. Cellulardensity was assessed on sections involving invasion and
adjacent to the cartilage by counting the cells in three
high-power fields at 400× magnification. Histological
assessments were made under double-blind conditions.
Three animal researchers recorded the data on separate
case record forms without exchanging any information.
Immunohistochemical staining was performed using a
streptavidin/peroxide kit (Zymed, San Francisco, CA,
USA) according to the manufacturer’s instructions. The
monoclonal antibody used was mouse anti-human MMP-9
antibodies (Santacruise, Dallas, TX, USA). Staining inten-
sity was assessed on a semiquantitative five-point scale
(0 = absent, 1 = weak, 2 =moderate, 3 = high, and 4 = very
high). Histologic assessment was evaluated in a blinded
manner by experienced pathologists.
Serum cytokine detection by cytometric bead array
The blood of sacrificed mice was obtained by heart punc-
ture 9 weeks after implantation and six human cytokines
(TNFα, IL-1β, IL-6, IL-8, IL-10 and IL-12p70) in serum
were analyzed simultaneously using a cytometric bead array
(BD Biosciences) according to the manufacturer’s manual.
Briefly, 50 μl of each sample or standard (0 to 5,000 pg/ml)
were added into 50 μl mixtures (capture antibody-bead
reagent and detector antibody-phycoerythrin reagent at a
volume of 1:1) and incubated at room temperature for
3 hours away from light. After washing to remove the un-
bound detection reagent, the mixtures were then loaded
onto flow cytometry and analyzed with cytometric bead
array software.
Gelatin zymogram
To study the influence of sdAbA1 on MMP secretion,
gelatin zymogram was performed. Briefly, cells (1 × 106
cell/well in 24-well plates) were starved for 24 hours,
and then pretreated with sdAbA1, sdAbE2 or CsA for
2 hours before CypA stimulation. After treatment with
CypA for 24 hours, the cell culture supernatants were
collected. Each sample was resolved by SDS-PAGE
under nonreducing conditions. The gels were then
washed twice in 2.5% (v/v) Triton X-100 for 30 minutes
at room temperature and incubated in reaction buffer
for 16 hours at 37°C. The gels were subsequently stained
with 0.5% Coomassie blue (R-250) and were destained to
visualize the zymogen bands. The zymography gels were
scanned and analyzed using US National Institutes of
Health (Bethesda, MD, USA) Image 1.6 software.
Cell chemotaxis inhibition assay
The mononuclear cells were obtained from heparinized
venous blood by the Ficoll-Hypaque (Sigma) gradient
centrifugation method. The chemotaxis assays were con-
ducted as described previously [9]. Briefly, the mono-
nuclear cells (1 × 106 cells/ml) were added to the upper
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containing CypA (100 ng/ml), N-formyl-Met-Leu-Phe
(FMLP, used as a positive control) or medium alone
were added to the lower compartments. The concentra-
tion of FMLP used was 10–7 M to induce optimal mono-
cyte migration. For blocking experiments, sdAbA1
(20 μg/ml), sdAbE2 (20 μg/ml) or CsA (2 μM) was
included in the lower wells. After incubation for 90
minutes, the number of cells appearing on the lower face
of the filter was counted under microscope for each well,
and each experimental condition was assayed in tripli-
cate. A chemotactic index was calculated for each well
by dividing the number of cells counted for that well by
the number of cells in wells containing medium alone.
Western blot analysis
THP-1 cells were plated in six-well plates and cultured in
serum-free RPMI 1640 medium for 18 hours. Following
this, the cells were pretreated with indicated concentrations
of sdAbA1, sdAbE2 or CsA for 2 hours before CypA stimu-
lation. For the mitogen-activated protein kinase inhibitor
and nuclear factor NF-κB inhibitor experiment, the
cells were pretreated with PD98059 (ERK1/2 inhibitor),
1-pyrrolidine carbodithioic acid, ammonium salt (PDTC,
NF-κB inhibitor) or N-tosyl-L-phenyl-alanylchloromethyl
ketone (TPCK, NF-κB inhibitor) for 2 hours before the
addition of CypA. After stimulation with CypA for 24 hours,
the cell culture supernatants were collected and tested in
two ways. One part of the supernatant was used to assay
the activity of MMP-9 by gelatin zymogram and by MMP-
9 activity assay kit (Ray Bio Tech, Guangzhou, China)
according to the manufacturers’ instructions. The other
part of the supernatant was used to measure the level of IL-
8 by a human CXCL8/IL-8 immunoassay kit (R&D System,
Emeryville, CA, USA). The expression of IκBα and NF-κB
P65 was observed 2 hours after CypA stimulation. The
levels of ERK and phosphor-ERK1/2 were measured 30 mi-
nutes after CypA treatment. Briefly, the cells were harvested
and the proteins were prepared with a commercial kit ac-
cording to the manufacturer’s instructions (KeyGEN, Nan-
jing, China). In brief, cells were incubated in 10 volumes of
hypotonic Buffer A on ice for 15 minutes and homoge-
nized. Nuclei were recovered by centrifugation at 16,000 × g
for 5 minutes, and the supernatant was collected as the
cytosolic extracts. The nuclei were extracted using Buffer C
for 40 minutes on ice. Insoluble material was removed by
centrifugation at 16,000 × g for 10 minutes, and the super-
natant was used as the nuclear extract. The extracts were
then separated by SDS-PAGE and transferred to PVDF
membrane (Millipore, Billerica, MA, USA ). Target bands
were blotted with various primary antibodies (anti-phos-
phor-ERK1/2, anti-ERK1/2, anti-p65 and anti-histone) and
horseradish peroxidase-conjugated secondary antibodies
were used to develop the membrane.Statistical analysis
Data are presented as the mean ± standard error of the
mean from three independent experiments unless other-
wise indicated. All statistical analyses were performed
using SPSS 15.0 statistical software (IBM SPSS, Chicago,
IL, USA). Statistical analysis of the density of total MMP,
inflammatory cell numbers, chemotactic index and
cytokine concentrations was carried out using Student’s
t test. In the CIA experiment, an independent-sample
t test was used to compare the clinical severity between
groups. Differences in cartilage invasion score, histologic
data, and bone erosion score between the treatments
groups were assessed by Kruskal–Wallis test followed by
the Mann–Whitney U test.
Results
Generation and characterization of single-domain
antibodies targeting cyclophilin A
A phage library of sdAbs was built from peripheral lympho-
cytes of the immunized animals and screened by the
phage-display technique. After three rounds of panning, ap-
proximately 200 clones were picked out randomly to obtain
the specific clones binding to CypA by phage ELISA. Four
positive sdAbs with strong binding activities were obtained,
expressed in Escherichia coli and purified. One of the iso-
lated sdAbs, sdAbA1, appeared more capable of inhibiting
cell migration and MMP secretion than the others and was
further investigated in this study. The expression and purifi-
cation of sdAbA1 in E. coli (HB2151) by immobilized metal
affinity chromatography followed by gel filtration is shown
in Figure 1A. The binding of sdAbA1 to recombinant CypA
was further evaluated by ELISA, where sdAbE2, which had
no detectable binding to CypA, was used as a negative con-
trol. As shown in Figure 1B, sdAbA1 displayed high levels
of binding to recombinant CypA, while the control sdAbE2
exhibited little binding. The binding affinity of sdAbA1 for
CypA was also determined by surface plasmon resonance,
yielding a ka of 5.67 × 105/M/second, a kd of 3.91 × 10–3/
second and a calculated KD of 6.9 × 10
–9 M (Figure 1C).
Previous studies have demonstrated that the PPIase ac-
tivity of CypA is crucial for its functions [24,25]. Here, we
also detected the influence of sdAbA1 on the PPIase
activity of CypA. The PPIase activity assay measures the
efficiency of PPIase-catalyzed cis–trans isomerization of a
commercially available tetrapeptide substrate that, follow-
ing cis conversion to the trans isomer, is recognized and
cleaved by chymotrypsin to result in yellow color forma-
tion. The addition of sdAbA1 significantly decreased the
rate of tetrapeptide cleavage catalyzed by CypA in a
concentration-dependent manner (Figure 1D).
Effects of the anti-CypA single-domain antibody A1 on CIA
For CIA in mice, sdAbA1 was intraperitoneally injected
at doses of 5 mg/kg without any toxic side effects. By
Figure 1 Characterization and identification of a novel single-domain antibody targeting cyclophilin A. (A) Expression and purification of anti-
CypA single-domain antibody (sdAb) A1. The sdAbA1 antibody was purified from periplasmic lysates by Ni-NTA columns followed by gel filtration. The
protein sample collected during purification was size fractionated by SDS-PAGE and stained with Coomassie blue. M, molecular weight markers, size
indicated in kDa; lane 1, total proteins in periplasmic lysates as loaded onto the column; lane 2, flowthrough obtained from the Ni-NTA column; lanes
3 and 4, proteins eluted from the Ni-NTA column and Superdex 75 prep grade column respectively. (B) Binding of sdAbA1 to cyclophilin A (CypA) was
detected by enzyme-linked immunosorbent assay. Purified CypA (1 μg/ml) was coated on 96-well plates and incubated with different concentrations
of sdAbA1 or sdAbE2 (control sdAb). Binding of sdAbs was detected with horseradish peroxidase-conjugated anti-his antibody, visualized with TMB
substrate and the plate was read at 450 nm. (C) Binding kinetics assay of sdAbA1 by surface plasmon resonance. (D) sdAbA1 inhibits the peptidyl-
prolyl cis–trans isomerase (PPIase) activity of CypA using a chymotrypsin-coupled assay. CypA (0.1 μM) is shown as a positive control for PPIase activity
and the absence of CypA and addition of CsA are used as blank control and negative control respectively. The presence of sdAbA1 inhibits the rate of
cleavage of the tetrapeptide substrate in a dose-dependent manner compared with CypA alone. (A) to (D) Data are representative results from three
independent experiments. ka, association rate constant; kd, dissociation rate constant; kD the equilibrium dissociation constant .
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treated and control animals. Nonimmunized and non-
treated animals did not develop any clinical signs of
arthritis (Figure 2A, normal). Immunized animals treated
with PBS or isotype control antibody served as positive
controls and developed severe clinical signs of arthritis
(Figure 2A, CIA + PBS and CIA + sdAbE2). Immunized
animals treated with sdAbA1 showed a significant de-
crease of clinical signs of arthritis (P <0.05) (Figure 2B).
The severity of bone damage was examined radio-
logically in healthy mice and in mice with CIA under
anesthesia. Joints in the hind paws were severely dam-
aged in the PBS-treated or sdAbE2-treated control
mice (Figure 2C,D, mean radiographic score 2.56 ± 0.38
in the PBS-treated group and 2.63 ± 0.31 in the isotype
control-treated group). A significant inhibition of joint
erosion could be observed in the mice injected with
5 mg/kg sdAbA1 (P < 0.05), and the mean radiographic
score was 1.62 ± 0.32 (Figure 2D).Effects of single-domain antibody A1 on inflammatory
cells in the implanted synovium and cartilage invasion
We also evaluated the effects of sdAbA1 treatment
on inflammation and cartilage destruction in the SCID-
HuRAg mice. Infliximab, a widely used and highly
effective treatment in RA, was applied as a positive
control. The inflammatory cells were observed in the
implanted tissues using hematoxylin and eosin staining
(representative photographs in Figure 3A). The number
of inflammatory cells in both the sdAbA1 treatmentgroup (254 ± 66 cells) and the infliximab group (238 ±
54 cells) were significantly lower (P <0.05) than those
of the control antibody group (389 ± 86 cells). No sig-
nificant differences were observed between the control
antibody and PBS-treated groups (415 ± 89) (shown in
Figure 3B).
Histological results showed that the cartilage erosion
was significantly less severe in the sdAbA1 group than
in the infliximab group (erosion score 2.58 ± 0.20) or the
control group (P <0.05). Deep invasion (invasion score
≥2.5) was observed in all six cartilage sections in the
control group (Figure 3C). The mean erosion score in
cartilage sections of the sdAbA1 group was 1.75 ± 0.27
(Figure 3D), compared with 2.75 ± 0.27 in the control
antibody group (P <0.05; n = 6 per group). No significant
differences were observed between the control antibody
and PBS-treated groups (2.83 ± 0.26).Effects of single-domain antibody A1 on MMP-9 expression
in the implanted synovium and inflammatory cytokines
levels in the serum
To clarify the mode and mechanism of action of sdAbA1,
we assessed the effects of sdAbA1 on cytokine secretion
and MMP expression. Immunohistochemical analysis
demonstrated that treatment of mice with sdAbA1
significantly decreased the expression of MMP-9 compared
with the PBS-treated group or the isotype antibody-treated
group (Figure 4A,B) (P <0.01). Interestingly, there were no
significant changes in MMP-9 production between the
infliximab-treated group and control groups (P >0.05).
Figure 2 Therapeutic administration of anti-CypA single-domain antibody A1 decreases arthritis severity in the collagen-induced
arthritis model. Mice with collagen-induced arthritis (CIA) were intraperitoneally injected with phosphate-buffered saline (PBS), isotype control
antibody, or single-domain antibody (sdAb) A1 once a day from 27 to 37 days (n = 10 per group). Nonimmunized and nontreated animals were
used as negative controls. (A) Representative photographs of the hind paw of CIA mice on day 42. (B) Clinical scoring was carried out as de-
scribed in Materials and methods. sdAbA1 significantly reduced the clinical arthritis severity in CIA mice (*P <0.05 vs. control antibody group, for
area under the curve). (C) Representative radiographs of the hind paw of CIA on day 42. (D) The degree of bone erosion on the radiographs of
the hind paws of the mice was scored on a scale of 0 to 3 as described in Materials and methods. Values are the mean ± standard error of the
mean of 10 mice per group. *P <0.05 versus control antibody group.
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inflammatory cytokines IL-6 and IL-8 were significantly
lower in the sdAbA1 group than in the control antibody
(P <0.05) and PBS-treated (P <0.05) groups. Notably, the
levels of all tested cytokines (TNFα, IL-1β, IL-6, IL-8,
and IL-12p70) were significantly lower in the infliximab
group compared with the control antibody group. In this
study, the amount of IL-10 was not shown any differ-
ence in different groups.
Single-domain antibody A1 inhibits MMP-9 secretion and
the chemotaxis induced by cyclophilin A
To further study the mechanism of action of sdAbA1,
we tested the effects of sdAbA1 on the MMP-9 secre-
tion and cell chemotaxis induced by CypA using the
monocytes/macrophages from RA patients. Firstly, to
determine the impact of sdAbA1 on the ability of CypA
to regulate MMP production, gelatin zymogram was
performed. The representative photographs of gelatin
zymogram using culture supernatants of monocytes/macrophages from THP-1, RA patients’ peripheral
blood and RA synovial fluid are shown in Figure 5A,C,
E, respectively. As shown in Figure 5D, the density of
total MMP-9 in monocytes (888 ± 133) and macro-
phages (2524 ± 248) from RA patients’ peripheral blood
with CypA stimulation was higher than that in the con-
trol group (329 ± 49 in monocytes, 1,052 ± 206 in mac-
rophages; P <0.001), and decreased markedly when
adding sdAbA1 (337 ± 58 in monocytes, 987 ± 103 in
macrophages; P <0.001) or CsA (345 ± 54 in mono-
cytes, 996 ± 192 in macrophages; P <0.001). Similarly,
the density of total MMP-9 in monocytes/macrophages
from RA synovial fluid with CypA stimulation (235 ±
23; P <0.001) was higher than that in the control group
(100 ± 20), and reduced when adding sdAbA1 (83 ± 19;
P <0.001) or CsA (89 ± 20; P <0.01) (Figure 5F). No
changes were observed by the isotype antibody control
sdAbE2 (P >0.05). Neither sdAbA1 nor CsA had any in-
fluence on pro-MMP-2 secretion (P >0.05). Since the
THP-1 cells were selected for functional experiments,
Figure 3 Effects of single-domain antibody A1 on implanted synovium and cartilage erosion in SCID-HuRAg mice. Rheumatoid arthritis
(RA) synovium with normal human articular cartilage was co-implanted under the back muscle chamber of SCID-HuRAg mice. After 4 weeks of
treatment, the co-implants were taken and stained with hematoxylin and eosin, and were evaluated histologically under a microscope. (A) Representative
image of implanted synovium in SCID-HuRAg mice in each treatment group (n = 6 per group) (magnification × 400). (B) Statistical results of
the numbers of inflammatory cells in each treatment group. (C) Representative images of human cartilage erosion in SCID-HuRAg mice of
different groups (magnification × 200). (D) Cartilage erosion score after treatment in each group. Black arrows, invasive front of the synovial
tissue. c, cartilage. *P <0.05 versus control antibody group. PBS, phosphate-buffered saline; sdAb, single-domain antibody.
Wang et al. Arthritis Research & Therapy 2013, 15:R208 Page 8 of 13
http://arthritis-research.com/content/15/6/R208we also assayed the influence of sdAbA1 on MMP se-
cretion in THP-1 cells under CypA stimulation. Similar
to the results in the monocytes/macrophages from RA
patients, the density of total MMP-9 in undifferentiated
THP-1 (1,128 ± 106) and differentiated THP-1 (THP-1,Figure 4 Anti-CypA single-domain antibody A1 suppresses matrix me
in SCID-HuRAg mice. (A) Representative images of matrix metalloproteina
(n = 6 per group) (magnification × 400). (B) Statistical results for the express
mice was obtained and the levels of cytokines were detected by cytometri
error of the mean with n = 6 per group. *P <0.05 compared with the contr
immunohistochemistry; IL, interleukin; PBS, phosphate-buffered saline; sdAb2,988 ± 210) cells with CypA stimulation was higher
than that in the control group (434 ± 60 in undifferenti-
ated THP-1, 1,245 ± 116 in differentiated THP-1; P
<0.001), and was markedly reduced by adding sdAbA1
(415 ± 61 in undifferentiated THP-1, 1,199 ± 133 intalloproteinase-9 and human inflammatory cytokine production
se (MMP)-9 staining of each treatment group under a microscope
ion of MMP-9 in each treatment group. (C) The blood of sacrificed
c bead array (CBA). Results are expressed as the mean ± standard
ol antibody group, **P <0.01 versus control antibody group. IHC,
, single-domain antibody; TNF, tumor necrosis factor.
Figure 5 Anti-CypA single-domain antibody A1 inhibits cell migration and matrix metalloproteinase production in human monocytes/
macrophages. The production of total matrix metalloproteinase (MMP)-9 and MMP-2 were tested by gelatin zymogram. (A), (C) and (E)
Representative photographs of gelatin zymogram using culture supernatants of monocytes/macrophages derived from THP-1, rheumatoid
arthritis (RA) patients’ peripheral blood and RA synovial fluid (SF) respectively. (B), (D) and (F) Statistical results of the density of total MMP-9 and
MMP-2 produced by monocytes/macrophages derived from THP-1, RA patients’ peripheral blood and RA SF respectively. Data were results from
three independent experiments. The protein expression of total MMP-9 (including Pro-MMP-9 and MMP-9) is significantly inhibited by single
domain antibody (sdAb) A1 treatment. Each bar represents the mean ± standard error of the mean (SEM) of each group. (G) Cell migration
mediated by cyclophilin A (CypA) is blocked by anti-CypA sdAbA1 antibody. Chemotaxis assays were set up using the peripheral mononuclear
cells from RA patients incubated in the presence of a single dose of N-formyl-Met-Leu-Phe (FMLP, positive control) plus cyclosporine A (CsA) or
sdAbA1, a single dose of CypA (100 ng/ml) plus sdAbA1, CsA or control antibody sdAbE2 (no binding to CypA). A chemotactic index was
calculated for each group by dividing the number of migrated cells in test wells by the number of cells that migrated to medium alone. Bar
graphs show mean ± SEM for each group, with n = 3 wells per group. ###P <0.001 versus control group; **P <0.01, ***P <0.001 versus CypA group.
dTHP-1, differentiated THP-1; uTHP-1, undifferentiated THP-1.
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http://arthritis-research.com/content/15/6/R208differentiated THP-1; P <0.001) or CsA (403 ± 57 in
undifferentiated THP-1, 1,208 ± 125 in differentiated
THP-1; P <0.001) (Figure 5B). However, no significant
changes were observed in the pro-MMP-2 secretion
(P >0.05).
We then tested the effects of sdAbA1 on the cell
chemotaxis induced by CypA using the RA patients’
peripheral mononuclear cells. The CypA chemotactic
index for peripheral mononuclear cells (4.14 ± 0.74) was
higher than that in the control group (1.00 ± 0.14,
P <0.001). The chemotactic index decreased significantly
when sdAbA1 or CsA was added (1.45 ± 0.36 and 1.21 ±
0.21, respectively; P <0.001) (Figure 5G). No significantFigure 6 Single-domain antibody A1 inhibits the production of MMP-
signaling pathway. (A) THP-1 cells were pretreated with different concen
for 2 hours before cyclophilin A (CypA) stimulation. The expression of cytop
protein and phosphorylation of ERK1/2 at 30 minutes were analyzed by we
protein were used as internal control respectively. (B) THP-1 cells were pret
and NF-κB-p65 protein at 2 hours and matrix metalloproteinase (MMP)-9 ac
blot and (C) gelatin zymography separately. (D), (E), (F) THP-1 cells were p
and N-tosyl-L-phenyl-alanylchloromethyl ketone (TPCK) (two inhibitors of N
supernatants were collected and the activity of MMP-9 determined using g
activity immunoassay kit (E) separately. The level of interleukin (IL)-8 in the
CA, USA) human CXCL8/IL-8 immunoassay kit (F) according to the manufa
independent experiments. (E), (F) Bar graphs show the mean ± standard error
<0.01 versus control group; *P <0.05, **P <0.01 versus CypA group.differences in chemotactic index were observed among
the groups treated with CypA alone versus those treated
with CypA plus sdAbE2 (P >0.05). Importantly, neither
sdAbA1 nor CsA had any effect on FMLP-induced
migration of cells, demonstrating that inhibition was
specific for CypA.
Single-domain A1 counteracts the positive impacts of
cyclophilin A on MMP-9 secretion and NF-κB activity via
the ERK pathway
We tested whether the inhibitory effects of sdAbA1 on
MMP-9 expression were dependent on NF-κB activation.
As shown in Figure 6A, sdAbA1 treatment significantly9 and IL-8 stimulated by cyclophilin A through the ERK–NF-κB
trations of single-domain antibody (sdAb) A1 or cyclosporine A (CsA)
lasmic IκBα, nuclear factor NF-κB-p65 at 2 hours, the level of ERK1/2
stern blot, while β-actin of cytoplasm protein and histone of nuclear
reated with PD98059 for 2 hours before adding CypA. The level of IκBα
tivity at 24 hours after CypA stimulation were determined by western
retreated with 1-pyrrolidine carbodithioic acid, ammonium salt (PDTC)
F-κB) for 2 hours before adding CypA. After 24 hours, the culture
elatin zymogram (D) and the Ray Bio Tech (Guangzhou, China) MMP-9
culture supernatants was also tested by the R&D Systems (Emeryville,
cturer’s instructions. (A) to (D) Data are representative results from three
of the mean for each group, with n = 3 wells per group. #P <0.05, ##P
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translocation of NF-κB P65 into the nucleus stimulated
by CypA in a dose-dependent manner. To further
explore the upstream regulatory molecules leading to
the inhibition of NF-κB, we analyzed the activities of the
mitogen-activated protein kinases. Treatment with CypA
combined with 5, 10, and 20 μg/ml sdAbA1 decreased
the p-ERK1/2 level by 47.23 ± 3.45%, 61.64 ± 3.85%, and
74.25 ± 3.76%, respectively, compared with treatment
with CypA alone. To demonstrate that sdAbA1 inhibits
the activation of NF-κB through the ERK pathway, thus
leading to decreases of MMP-9 production, PD98059
(an inhibitor of ERK) was used. No significant differ-
ences were observed in the degradation of cytoplasmic
IκBα or the translocation of NF-κB P65 among the
groups treated with sdAbA1, PD98059 or sdAbA1 asso-
ciated with PD98059 (P >0.05) (Figure 6B). Similar
results were observed in pro-MMP-9 secretion by gel-
atin zymography (Figure 6C). All of these results suggest
that sdAbA1 was able to reverse the NF-κB activity and
MMP-9 expression induced by CypA through the ERK
pathway.
Effects of NF-κB inhibitors on MMP-9 secretion and IL-8
expression
To further demonstrate that CypA-induced MMP-9
expression and IL-8 secretion requires NF-κB activation,
THP-1 cells were pretreated with the TPCK and PDTC
inhibitors of NF-κB before CypA stimulation. Both of
these inhibitors significantly blocked the CypA-induced
MMP-9 expression (Figure 6D) and IL-8 secretion
(P <0.05; Figure 6F). As shown in Figure 6E, the levels
of MMP-9 reduced dramatically on adding NF-κB
inhibitors (P <0.01). The amounts of IL-8 decreased
significantly from 964.89 ± 199.26 pg/ml (CypA stimula-
tion group) to 433.78 ± 91.00 pg/ml (PDTC, 20 μM)
and 427.11 ± 63.65 pg/ml (TPCK, 10 μM), respectively
(P <0.05). Moreover, we also observed in the sdAbA1
treatment group that the production of IL-8 decreased
markedly (P <0.05 in Figure 6F) compared with that in
the CypA treatment group, indicating that sdAbA1 was
able to decrease IL-8 secretion induced by CypA
through inhibiting the activation of NF-κB.
Discussion
Although treatments for RA targeting TNFα or IL-1β
have proved effective for many patients, there are still
some problems to be solved – such as the nonuniversal
adequacy and maintenance of response and risks of ad-
verse effects like infection and malignancy. New targets
in the treatment of RA therefore need to be investigated.
CypA, a widely distributed intracellular protein, was
secreted by cells in response to inflammatory stimuli.
Extracellular CypA is now commonly referred to as acytokine involved in several different inflammatory
diseases, including RA. CypA played an important role
in the pathogenesis of human RA [6-9], as well as in
CIA [26], thus providing an attractive target for thera-
peutic interventions. In the present study, we identified
a novel anti-CypA antibody sdAbA1 and demonstrated
its therapeutic potential for RA. Treatment with sdAbA1
ameliorated arthritis severity and joint destruction in two
different models for RA. This was associated with reduc-
tions in inflammatory cell numbers, MMP expression, and
proinflammatory cytokines that are well known for their
critical role in inducing inflammation and bone erosion.
It is well known that each animal model cannot reflect
the complexity of human disease. In order to evaluating
the effects of the novel anti-CypA antibody sdAbA1 on
RA, two different animal models of RA, the CIA model
and the SCID-HuRAg mouse model, were adopted.
Since the disease onset in CIA model varies widely for
each mouse, 100 mice were used to construct the model.
When mice showed clinical symptoms, 30 arthritic mice
with a clinical arthritis score (1 to 3 on day 27) were
chosen to receive different treatments. The initial disease
severity of these arthritic mice is similar, and thus the
results could more readily reflect the true efficacy of dif-
ferent treatments. A significant decrease in the clinical
arthritis score as well as joint damage was observed in
the sdAbA1 group. In the SCID-HuRAg model, our data
showed remarkable reductions in the number of inflam-
matory cells and the degree of cartilage erosion in the
sdAbA1-treated group compared with the control group.
Moreover, sdAbA1 treatment prevented cartilage de-
struction more effectively than the drug infliximab.
It has been well established that proinflammatory
cytokines and MMPs are involved in the pathogenesis of
RA [2,3]. CypA may stimulate macrophages to degrade
joint cartilage via MMP-9 expression and promote
inflammation via proinflammatory cytokine production
[7,8]. In this study, immunohistochemical staining
revealed that the MMP-9 expression in the grafts was re-
markably lower in the sdAbA1-treated group compared
with the control group. The ability of sdAbA1 to inhibit
MMP-9 production may explain why sdAbA1 exhibited
stronger anti-erosion effects than the anti-TNFα mono-
clonal antibody. In addition, the serum levels of IL-6 and
IL-8 in the SCID-HuRAg model were significantly
reduced following sdAbA1 treatment. These findings
indicate that sdAbA1 exerts anti-inflammatory and anti-
joint damage effects on RA by inhibiting MMP-9 expres-
sion and secretion of IL-6 and IL-8.
Although it is largely unclear how CypA is involved in
chemotaxis and MMP-9 regulation, one critical mechan-
ism occurs via the interaction of CypA with one of its
receptors, EMMPRIN (CD147) [27-29]. A study re-
ported that fibroblast-like synoviocytes from CIA mice
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rophages [30]. In RA patients, upregulated expression of
CD147 was also found on circulating and synovial
monocytes/macrophages [31], and high levels of CypA
were also detected in the synovial fluid [6]. These re-
ports suggest that an interaction in the synovial joints
between extracellular CypA and CD147 expressed by
macrophages may be a mechanism involved in the devel-
opment of RA. Interestingly, we found that sdAb1 could
block the CypA–CD147 interactions by carrying out
competitive ELISA (data not shown). To further clarify
the mechanism of the therapeutic effects of sdAbA1 on
RA, CypA was added into monocytes/macrophages from
RA patients in vitro to mimic an in vivo environment of
rheumatic joints. Our results showed that cell migration
and MMP-9 secretion of RA patients’ monocytes/macro-
phages were remarkably inhibited by sdAbA1. Moreover,
western blot results demonstrated that sdAbA1 was able
to reverse the NF-κB activity induced by CypA through
the ERK pathway, thus leading to downregulation of
MMP-9. In order to explore the relationship between
NF-κB activation and MMP-9 production, the two NF-
κB inhibitors TPCK and PDTC were used. This method
showed that the levels of MMP-9 reduced dramatically
by adding NF-κB inhibitors. Other studies also sug-
gested that CD147 mediate the effects of extracellular
CypA via inducing the activation of NF-κB [8,32],
which was consistent with our results. These studies
therefore suggested that sdAbA1 may block the inter-
action between CypA and CD147 and inhibit NF-κB
activation through ERK1/2, thus leading to the down-
regulation of MMP-9.
Furthermore, IL-8 secretion stimulated by CypA was
reduced by adding to either sdAbA1 or NF-κB inhibitors
in vitro. However, other studies have reported that
knockdown of CD147 does not result in change in
CypA-mediated stimulation of IL-8, suggesting that
CD147 is not the only cellular receptor of extracellular
CypA [32]. The exact mechanisms behind the IL-8 in-
hibition by sdAbA1 treatment remain to be further elu-
cidated. Interestingly, our results indicate that NF-κB
may be involved.
Conclusions
In summary, we identified a novel sdAbA1 that neutral-
izes CypA, which decreases both cartilage/bone erosion
and synovial inflammation in two different animal
models through inhibition of the ERK–NF-κB pathway.
This characterization of the anti-CypA sdAbA1 could
help to develop new strategies for the control of RA.
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